Abstract | PURPOSE: MATERIALS METHODS: RESULTS: CA9 reference single nucleotide polymorphisms rs2071676, rs12553173, rs3829078 and rs1048638 were found in 59%, 15%, 11% and 33% of patients, respectively. The deletion c.376del393 was observed in 2 patients. CAIX expression was greater than 85% in 65% of patients. No single nucleotide polymorphisms were significantly associated with CAIX expression. Patients with the C allele variant of rs12553173 had improved median survival (27.3 vs 13.6 months, p = 0.0431) and a greater likelihood of an interleukin-2 response (57% vs 22%, p = 0.081) Likewise high CAIX expression was associated with longer median survival (25.5 vs 8.5 months, p <0.0001) and a greater interleukin-2 response rate (37% vs 8%, p = 0.070). In a multivariate Cox model the C allele variant of CA9 single nucleotide polymorphism rs12553173 and CAIX expression were retained as independent prognostic factors. CONCLUSIONS: CA9 single nucleotide polymorphisms are common in patients with metastatic clear cell renal cell carcinoma. The synonymous C allele variant of rs12553173 may be associated with improved overall survival and a greater likelihood of a response to interleukin-2. CA9 rs12553173 and CAIX are independent prognostic factors of overall survival and complementary for predicting the prognosis of metastatic clear cell renal cell carcinoma.
|
Authors | Michela de Martino, Tobias Klatte, David B Seligson, Jeffrey LaRochelle, Brian Shuch, Randy Caliliw, Zhenhua Li, Fairooz F Kabbinavar, Allan J Pantuck, Arie S Belldegrun |
Journal | The Journal of urology
(J Urol)
Vol. 182
Issue 2
Pg. 728-34
(Aug 2009)
ISSN: 1527-3792 [Electronic] United States |
PMID | 19539328
(Publication Type: Journal Article)
|
Chemical References |
- Antigens, Neoplasm
- Antineoplastic Agents
- Interleukin-2
- CA9 protein, human
- Carbonic Anhydrase IX
- Carbonic Anhydrases
|
Topics |
- Adult
- Aged
- Antigens, Neoplasm
(genetics)
- Antineoplastic Agents
(therapeutic use)
- Carbonic Anhydrase IX
- Carbonic Anhydrases
(genetics)
- Carcinoma, Renal Cell
(drug therapy, genetics, mortality, secondary)
- Female
- Humans
- Interleukin-2
(therapeutic use)
- Kidney Neoplasms
(drug therapy, genetics, mortality, pathology)
- Male
- Middle Aged
- Polymorphism, Single Nucleotide
- Prognosis
- Survival Rate
|